NASDAQ:AGENAgenus Stock Price, Forecast & News

$2.50

0.00 (0.00 %)

(As of 05/25/2020 04:00 PM ET)

Add

Compare

Today's Range

$2.46

Now: $2.50▼

$2.60

50-Day Range

$2.29

MA: $2.56▼

$2.83

52-Week Range

$1.82

Now: $2.50▼

$4.57

Volume2.20 million shs

Average Volume2.24 million shs

Market Capitalization$418.46 million

P/E RatioN/A

Dividend YieldN/A

Beta1.95

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neoantigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neoepitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Agenus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.00, Agenus has a potential upside of 140.0% from its current price of $2.50.
Amount of Analyst Coverage
Agenus has only been the subject of 1 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
Agenus has received 428 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Agenus has received 334 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Agenus has received 56.17% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote “Outperform” if you believe AGEN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Agenus does not currently pay a dividend.
Dividend Growth
Agenus does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Agenus insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.70% of the stock of Agenus is held by insiders.
Percentage Held by Institutions
46.74% of the stock of Agenus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Agenus are expected to grow in the coming year, from ($1.14) to ($1.13) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Agenus is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Agenus is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Overall Beat the Market Rank^™

1.59 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:AGEN

Previous Symbol

CUSIP00847G70

CIK1098972

Webagenusbio.com

Phone781-674-4400

Debt

Debt-to-Equity RatioN/A

Current Ratio0.81

Quick Ratio0.81

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$150.05 million

Price / Sales2.79

Cash FlowN/A

Price / Cash FlowN/A

Book Value($1.68) per share

Price / Book-1.49

Profitability

EPS (Most Recent Fiscal Year)($0.80)

Net Income$-107,660,000.00

Net Margins-204.33%

Return on EquityN/A

Return on Assets-97.23%

Miscellaneous

Employees294

Outstanding Shares167,384,000

Market Cap$418.46 million

Next Earnings Date8/13/2020 (Estimated)

OptionableOptionable

Receive AGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter.

Agenus (NASDAQ:AGEN) Frequently Asked Questions

How has Agenus' stock been impacted by COVID-19 (Coronavirus)?

Agenus' stock was trading at $2.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AGEN shares have decreased by 8.1% and is now trading at $2.50. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Agenus?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Agenus.

When is Agenus' next earnings date?

Agenus is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Agenus.

How were Agenus' earnings last quarter?

Agenus Inc (NASDAQ:AGEN) released its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.31) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.33) by $0.02. The biotechnology company had revenue of $15.13 million for the quarter, compared to analysts' expectations of $12.35 million. View Agenus' earnings history.

What price target have analysts set for AGEN?

1 brokerages have issued 12-month price targets for Agenus' shares. Their forecasts range from $6.00 to $6.00. On average, they anticipate Agenus' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 140.0% from the stock's current price. View analysts' price targets for Agenus.

Has Agenus been receiving favorable news coverage?

News headlines about AGEN stock have been trending somewhat positive recently, according to InfoTrie. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Agenus earned a news impact score of 0.8 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutAgenus.

Are investors shorting Agenus?

Agenus saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 15,210,000 shares, an increase of 8.7% from the March 31st total of 13,990,000 shares. Based on an average daily trading volume, of 2,400,000 shares, the short-interest ratio is presently 6.3 days. Approximately 11.7% of the shares of the company are short sold. View Agenus' Current Options Chain.

Who are some of Agenus' key competitors?

Some companies that are related to Agenus include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

What other stocks do shareholders of Agenus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agenus investors own include Rosetta Genomics (ROSG), Exelixis (EXEL), REDHILL BIOPHAR/S (RDHL), Merrimack Pharmaceuticals (MACK), Opko Health (OPK), Gilead Sciences (GILD), Novavax (NVAX), Energy Transfer LP Unit (ET), Sorrento Therapeutics (SRNE) and Inovio Pharmaceuticals (INO).

Who are Agenus' key executives?

Agenus' management team includes the following people:

Dr. Garo H. Armen, Founder, Exec. Chairman & CEO (Age 66)
Dr. Jennifer Buell, Chief Operating Officer
Dr. Alexander R. Duncan, CTO & Head of Research (Age 57)
Dr. Christian Cortis, Chief Strategy Officer & Head of Fin. (Age 51)
Ms. Christine M. Klaskin, Principal Accounting Officer & VP of Fin. (Age 53)

What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

Who are Agenus' major shareholders?

Agenus' stock is owned by a variety of retail and institutional investors. Top institutional investors include Cormorant Asset Management LP (7.27%), BlackRock Inc. (6.13%), Oracle Investment Management Inc. (3.20%), State Street Corp (2.31%), Geode Capital Management LLC (0.93%) and Wells Fargo & Company MN (0.67%). View institutional ownership trends for Agenus.

Which institutional investors are selling Agenus stock?

AGEN stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Morgan Stanley, Squarepoint Ops LLC, Connor Clark & Lunn Investment Management Ltd., BlackRock Inc., State Street Corp, UBS Group AG, and Alps Advisors Inc.. View insider buying and selling activity for Agenus.

Which institutional investors are buying Agenus stock?

AGEN stock was bought by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Oracle Investment Management Inc., Two Sigma Advisers LP, Cadence Capital Management LLC, Russell Investments Group Ltd., Nuveen Asset Management LLC, Wells Fargo & Company MN, and Trellus Management Company LLC. View insider buying and selling activity for Agenus.

How do I buy shares of Agenus?

Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Agenus' stock price today?

One share of AGEN stock can currently be purchased for approximately $2.50.

How big of a company is Agenus?

Agenus has a market capitalization of $418.46 million and generates $150.05 million in revenue each year. The biotechnology company earns $-107,660,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Agenus employs 294 workers across the globe.

What is Agenus' official website?

The official website for Agenus is agenusbio.com.

How can I contact Agenus?

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff